Synonyms: PA-824 | PA824
pretomanid is an approved drug (FDA (2019), EMA (2020))
Compound class:
Synthetic organic
Comment: Pretomanid is a nitroimidazole-based antibacterial used for the treatment of multi-drug-resistant pulmonary tuberculosis [3]. It is active against replicating and non-replicating Mycobacterium tuberculosis [1]. Pretomanid was developed by the non-profit organisation TB Alliance (www.tballiance.org.za).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Aher RB, Sarkar D. (2021)
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating Mycobacterium tuberculosis. J Biomol Struct Dyn, 39 (3): 889-900. [PMID:31983295] |
2. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J et al.. (2020)
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 382 (10): 893-902. [PMID:32130813] |
3. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN et al.. (2000)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 405 (6789): 962-6. [PMID:10879539] |
4. (2012)
Pretomanid. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury,. [PMID:31869193] |